A phase 1 trial (NCT02027961) investigated the combination of durvalumab (anti-PD-L1) with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in patients with BRAF-mutated melanoma as well as durvalumab and trametinib given concurrently or sequentially in patients with BRAF wild-type melanoma. Here, MAP2K7 is linked to melanoma.